Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Investigating How the Tumour Immune Microenvironment Predisposes the Cardiovascular System to Chemotherapy-Induced Cardiotoxicity

EF 2023-24

Résumé
Dr. Jason Fish, University of Toronto. While significant improvements in chemotherapy treatments have greatly enhanced the survivorship of cancer patients, the strides made in defeating their cancer become overshadowed by the looming threat of heart disease in their future. Chemotherapy can damage blood vessels and the heart, but it is difficult to know which cancer patients will develop heart disease during or after chemotherapy. If we could identify these patients, timely treatment for heart disease or adjustments to their cancer treatment can be implemented into their care, thus drastically improving their quality-of-life post-chemotherapy. Our lab has identified potential biomarkers for chemotherapy-induced heart disease that are indicative of cardiovascular damage and inflammation. Intriguingly, some of these markers were elevated in those that later developed heart disease, prior to starting cancer therapy and were not associated with cardiovascular risk factors. This has led us to investigate if cancer-derived factors enhance the vulnerability of the cardiovascular system to chemotherapy-induced heart disease. To study this, we will use human breast cancer samples and a mouse model of cancer to 1) determine the level of cardiovascular damage and inflammation caused by the cancer itself, and 2) investigate how chemotherapy increases damage and inflammation of the cardiovascular system leading to heart disease and 3) investigate the inflammatory state of human breast cancer biopsies to determine if factors in the cancer itself correlate with circulating markers of cardiovascular damage and inflammation. Currently, it is unknown if components of the tumour contribute to the risk of chemotherapy-induced cardiac dysfunction. Our study will test this novel paradigm to ultimately reveal new prognostic markers of chemotherapy-induced heart disease and potential therapeutic targets that will significantly improve cancer survivorship by preventing heart failure.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
495744
Name
Mistry Priya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Investigating How the Tumour Immune Microenvironment Predisposes the Cardiovascular System to Chemotherapy-Induced Cardiotoxicity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Biomarkers; Breast Cancer; Cancer Survivorship; Cardio-Oncology; Chemotherapy; Endothelial Activation; Heart Failure; Spatial Proteomics; Systemic Inflammation; Tumour Microenvironment
Abstract
Dr. Jason Fish, University of Toronto. While significant improvements in chemotherapy treatments have greatly enhanced the survivorship of cancer patients, the strides made in defeating their cancer become overshadowed by the looming threat of heart disease in their future. Chemotherapy can damage blood vessels and the heart, but it is difficult to know which cancer patients will develop heart disease during or after chemotherapy. If we could identify these patients, timely treatment for heart disease or adjustments to their cancer treatment can be implemented into their care, thus drastically improving their quality-of-life post-chemotherapy. Our lab has identified potential biomarkers for chemotherapy-induced heart disease that are indicative of cardiovascular damage and inflammation. Intriguingly, some of these markers were elevated in those that later developed heart disease, prior to starting cancer therapy and were not associated with cardiovascular risk factors. This has led us to investigate if cancer-derived factors enhance the vulnerability of the cardiovascular system to chemotherapy-induced heart disease. To study this, we will use human breast cancer samples and a mouse model of cancer to 1) determine the level of cardiovascular damage and inflammation caused by the cancer itself, and 2) investigate how chemotherapy increases damage and inflammation of the cardiovascular system leading to heart disease and 3) investigate the inflammatory state of human breast cancer biopsies to determine if factors in the cancer itself correlate with circulating markers of cardiovascular damage and inflammation. Currently, it is unknown if components of the tumour contribute to the risk of chemotherapy-induced cardiac dysfunction. Our study will test this novel paradigm to ultimately reveal new prognostic markers of chemotherapy-induced heart disease and potential therapeutic targets that will significantly improve cancer survivorship by preventing heart failure.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mistry, Priya
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~